| ABSTRACT Objective:To rapidly assess the efficacy, safety and economics of sevelamer in treating dialysis patients with hyperphosphatemia. Methods:Electronic databases including PubMed, Embase, the Cochrane Library, and relevant health technology assessment databases were systematically searched to collect the health technology assessment reports, systematic reviews/Meta analyses, and economic analyses that evaluate sevelamer in treating dialysis patients with hyperphosphatemia. We selected studies according to inclusion and exclusion criteria, extracted data, assessed the quality, and then made the conclusions after comprehensive analysis of the evidence. Results:22 studies were selected, including 5 health technology assessment reports, 7 systematic reviews/Meta analyses, and 10 economic analyses. The results showed that sevelamer was efficient in controlling serum phosphorus levels, without increasing the serum calcium levels and risk of hypercalcemia. Patients treated with sevelamer had lower total cholesterol, LDL cholesterol, and C reactive protein, and without over inhibition of serum intact parathyroid hormone levels. The results from economic analyses from both China and abroad showed that sevelamer was a cost effective option in treating dialysis patients with hyperphosphatemia, compared with calcium based phosphate binders. In China, sevelamer is likely to be a cost saving option compared to lanthanum, but further studies are still needed.Conclusion:Current available evidence supports use of sevelamer for treating dialysis patients with hyperphosphatemia. |
